Pediatric Vaccinations

This information can change. Please double check resources and continue to monitor them for up to date information.

On October 26th, the FDA's Vaccines and Related Biological Products Advisory Committee voted to amend Pfizer-BioNTech’s Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children ages 5 - 11. Following this announcement, the CDC passed its recommendation on Nov 2nd, which was then upheld by the Western States Scientific Review Workgroup on Nov 3rd. Currently, the Pfizer-BioNTech vaccine is the only EUA approved vaccine for ages 5-11. Moderna's pediatric vaccine for ages 6-11 is still being studied and is currently in phase 2 out of 3 of its clinical trials. However, Moderna will delay filing EUA requests for the pediatric vaccine while the FDA assesses the Moderna vaccines EUA on ages 12-17.

 

Is this vaccine different than the vaccine for ages 12+?

Based on the Preliminary information on Pfizer-BioNTech COVID-19 vaccines, it is a  separate vaccine formulation based on the same technology, more appropriately diluted for ages 5-11. Similarly, you child will need to receive a second dose of their vaccine at least 21 days after their first dose date. Please note: the preliminary information on the Pfizer-BioNTech vaccine is subject to change pending regulatory guidance from the FDA and CDC recommendations. 

 

Possible Side Effects

Your child may have some side effects, which are normal signs that their body is building protection and should go away in a few days. These may include:

  • pain or swelling at the injection site
  • a headache, chills
  • or fever

There have also been reports of myocarditis and pericarditis in adolescence and young adults, more often after the second dose than the first dose. However, these reports are rare and potential benefits of COVID-19 vaccination outweigh the known and potential risks, including the possible risk of myocarditis or pericarditis. Any adverse side effects can and should be reported to the Vaccine Adverse Event Reporting System (VAERS).

 

Efficacy

Based on the study Pfizer-BioNTech submitted to the FDA, the vaccine for ages 5-11 showed to be 90.7% effective. This is similar to the efficacy of the Pfizer-BioNTech vaccine for ages 12+. 

 

Will Oregon have enough vaccines to vaccinate all youth whose parents want them to be vaccinated?

Oregon will have 11,100 doses available to use immediately, with more allocations available starting in early November. Oregon Health Authority expect the supply will be adequate to meet the demand. You can also track how many vaccinations have been delivered to vaccination sites on the Oregon Health Authority dashboard here.

 

Other Concerns?

If you have any other questions or concerns for the Oregon Health Authority, you can make your voice heard by filling out this form

 

For more information and updates about pediatric vaccines click here.

To get notified when the vaccine becomes available for you children and find vaccination sites near close by, you can sign up on http://getvaccinated.oregon.gov/#/.